Validation of the IHE Cohort Model of Type 2 Diabetes and the Impact of Choice of Macrovascular Risk Equations-Reference-Cited by-同舟云学术

Validation of the IHE Cohort Model of Type 2 Diabetes and the Impact of Choice of Macrovascular Risk Equations

Published:2014-10-13 Issue:10 Volume:9 Page:e110235
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Lundqvist Adam,Steen Carlsson Katarina,Johansen Pierre,Andersson Emelie,Willis Michael

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference35 articles.

1. Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL, et al.. (2005) Methods for the economic evaluation of health care programme. Third edition: Oxford: Oxford University Press.

2. Guidelines for Computer Modeling of Diabetes and its Complications;Diabetes care,2004

3. Modelling methods for pharmacoeconomics and health technology assessment: an overview and guide;JE Stahl;Pharmacoeconomics,2008

4. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–3;U Siebert;Value Health,2012

5. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–7;DM Eddy;Value Health,2012

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse drug events in cost-effectiveness models of pharmacological interventions for diabetes, diabetic retinopathy, and diabetic macular edema: a scoping review;JBI Evidence Synthesis;2024-07-29

2. Examining the Impact of Structural Uncertainty Across 10 Type 2 Diabetes Models: Results From the 2022 Mount Hood Challenge;Value in Health;2024-07

3. A Systematic Review of Methodologies Used in Models of the Treatment of Diabetes Mellitus;PharmacoEconomics;2023-09-22

4. A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus;PharmacoEconomics;2023-07-06

5. Cost-Effectiveness of Semaglutide vs. Empagliflozin, Canagliflozin, and Sitagliptin for Treatment of Patients with Type 2 Diabetes in Denmark: A Decision-Analytic Modelling Study;PharmacoEconomics - Open;2023-05-13